Sylentis is a European biotechnological company founded in 2006. Specializing in researching new therapeutic approaches based on gene silencing, the company focuses on developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design.
The most advanced products of Sylentis are treatments for glaucoma and dry eye syndrome. As a wholly owned member of PharmaMar (www.pharmamar.com), Sylentis has positioned itself as an innovative player in the biotechnology industry.
With a dedicated focus on biotechnology, Sylentis presents an enticing opportunity for investment in the development of cutting-edge therapeutic solutions that address significant unmet medical needs in the ophthalmology market.
There is no investment information
No recent news or press coverage available for SYLENTIS.
We care about your data, and we'd love to use cookies make your experience better.
